Problems associated with biological markers of Alzheimer's disease

Neurochemical Research

Volumn 30, Issue 12, 2005, Pages 1501-1510

  Frey, H J ^a   Mattila, K M ^a,c   Korolainen, M A ^b   Pirttila T ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; Biological markers; Blood; Cerebrospinal fluid; Genetics; Imaging; Immunology; Proteins; Proteomics

Indexed keywords

24 S HYDROXYCHOLESTEROL; 3 NITROTYROSINE; 4 HYDROXYNONENAL; 8 HYDROXYGUANOSIDE; ACETYLCHOLINESTERASE; ALPHA 2 MACROGLOBULIN; AMYLOID PRECURSOR PROTEIN; ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL DERIVATIVE; CHYMOTRYPSIN ALPHA 1 ANTIBODY; CHYMOTRYPSINOGEN; COMPLEMENT; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; GUANOSINE DERIVATIVE; ISOPROSTANE DERIVATIVE; NEURONAL THREAD PROTEIN; NITRIC OXIDE; PROSTAGLANDIN DERIVATIVE; PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN S100B; RAB PROTEIN; SUPEROXIDE DISMUTASE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNAPTOTAGMIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; FOLLOW UP; GENETIC ANALYSIS; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; PROTEOMICS;

EID: 29244432517     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-005-8827-7     Document Type: Article

References (99)

1. A. Alzheimer 1907 Uber eine eigenartige Erkrankung der Hirnrinde Allg. Z. Psychiat. 64 146 148
2. G. G. Glenner C. W. Wong 1984 Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem. Biophys. Res. Commun. 120 885 890
3. C. L. Masters G. Simms N. A. Weinman G. Multhaup B. L. [tmp] McDonald K. Beyreuther 1985 Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl. Acad. Sci. USA 82 4245 4249
4. D. J. Selkoe 1994 Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease Curr. Opin. Neurobiol. 4 708 716
5. F. Coria E. Castaño F. Prelli M. Larrondo-Lillo S. van Duinen M. L. Shelanski B. Frangione 1988 Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis Lab. Invest. 58 454 458
6. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease Cell 52 487 501
7. A. D. Snow J. Willmer R. Kisilevsky 1987 Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab. Invest. 56 120 124
8. 1-antichymotrypsin are in the lesions of Alzheimer's disease Neuroreport 3 201 203
9. T. Wisniewski B. Frangione 1992 Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid Neurosci. Lett. 135 235 238
10. O. Yasuhara H. Muramatsu S. U. Kim T. Muramatsu H. Maruta P. L. [tmp] McGeer 1993 Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease Biochem. Biophys. Res. Commun. 192 246 251
11. I. Grundke-Iqbal K. Iqbal M. Quinlan Y-C. Tung M. S. Zaidi H. M. Wisniewski 1986 Microtubule-associated protein tau. A component of Alzheimer paired helical filaments J. Biol. Chem. 261 6084 6089
12. H. Braak E. Braak 1991 Neuropathological stageing of Alzheimer-related changes Acta Neuropathol. 82 239 259
13. S. S. Mirra A. Heyman D. [tmp] McKeel S. M. Sumi B. J. Crain 1991 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): 2 Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 479 486
14. The National Institute on Aging Reagan Institute Working Group 1997 Consensus recommendations for the postmortem diagnosis of Alzheimer's disease Neurobiol. Aging 18 S1 S2
15. H. M. Wisniewski T. Pirttilä J. Wegiel 1998 Etiology and pathogenesis of Alzheimer's disease V. Kumar C. Eisdorfer Advances in the Diagnosis and Treatment of Alzheimer's Disease Springer Publishing Company New York 31 52
16. K. A. Jobst L. P. D. Barnetson B. J. Shepstone 1998 On behalf of the Oxford Project to investigate memory and aging. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias Int. Psychogeriatr. 10 271 302
17. C. M. Hulette K. A. Welsh-Bohmer M. G. Murray A. M. Saunders D. C. Mash L. M. [tmp] McIntyre 1998 Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals J. Neuropathol. Exp. Neurol. 57 1168 1174
18. D. G. Davis F. A. Schmitt D. R. Wekstein W. R. Markesbery 1999 Alzheimer neuropathologic alterations in aged cognitively normal subjects J. Neuropathol. Exp. Neurol. 58 376 388
19. Neuropathology Group of the Medical Research Council Cognitive Function Ageing Study (MRC CFAS) 2001 Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales Lancet 357 169 175
20. K. Jellinger W. Danielczyk P. Fischer E. Gabriel 1990 Clinicopathologic analysis of dementia disorders in the elderly J. Neurol. Sci. 95 239 258
21. O. L. Lopez J. T. Becker D. I. Kaufer R. L. Hamilton R. A. Sweet W. Klunk S. T. DeKosky 2002 Research evaluation and prospective diagnosis of dementia with Lewy bodies Arch. Neurol. 59 43 46
22. C. Haass M. G. Schlossmacher A. Y. Hung C. Vigo-Pelfrey A. Mellon B. L. Ostaszewski I. Lieberburg E. H. Koo D. Schenk D. B. Teplow 1992 Amyloid beta-peptide is produced by cultured cells during normal metabolism Nature 359 322 325
23. T. Pirttilä K. S. Kim P. D. Mehta H. Frey H. M. Wisniewski 1994 Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls J. Neurol. Sci. 127 90 95
24. M. Jensen J. Schroder M. Blomberg B. Engvall J. Pantel N. Ida H. Basun L. O. Wahlund E. Werle M. Jauss K. Beyreuther L. Lannfelt T. Hartmann 1999 Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression Ann Neurol. 45 504 511
25. P. D. Mehta T. Pirttilä 2002 Biological markers of Alzheimer's disease Drug Dev. Res. 51 1 11
26. T. Tapiola T. Pirttilä P. D. Mehta I. Alafuzoff M. Lehtovirta P. Riekkinen Sr. H. Soininen 2000 Relationship between apoE genotype and CSF β-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease Neurobiol. Aging 21 735 740
27. K. Blennow H. Hampel 2003 CSF markers for incipient Alzheimer's disease Lancet Neurol. 2 605 613
28. M. Otto J. Wiltfang H. Tumani I. Zerr M. Lantsch J. Kornhuber T. Weber H. A. Kretzschmar S. Poser 1997 Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurosci. Lett. 225 210 212
29. N. Andreasen L. Minthon E. Vanmechelen H. Vanderstichele P. Davidsson B. Winblad K. Blennow 1999 Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment Neurosci. Lett. 273 5 8
30. M. Riemenschneider N. Lautenschlager S. Wagenpfeil J. Diehl A. Drzezga A. Kurz 2002 Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment Arch. Neurol. 59 1729 1734
31. I. Skoog P. Davidsson O. Aevarsson H. Vanderstichele E. Vanmechelen K. Blennow 2003 Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds Dement. Geriatr. Cogn. Disord. 15 169 176
32. S. K. Herukka M. Hallikainen H. Soininen T. Pirttilä 2005 CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment Neurology 64 1294 1297
33. B. Wolozin P. Davies 1987 Alzheimer-related neuronal protein A68: specificity and distribution Ann. Neurol. 22 521 526
34. M. M. Verbeek D. de Jong H. P. H. Kremer 2003 Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases Ann. Clin. Biochem. 40 25 40
35. T. Tapiola M. Overmyer M. Lehtovirta S. Helisalmi J. Ramberg I. Alafuzoff P. J. Riekkinen Sr. H. Soininen 1997 The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease Neuroreport 8 3961 3963
36. F. P. Zemlan W. S. Rosenberg P. A. Luebbe T. A. Campbell G. E. Dean N. E. Weiner J. A. Cohen R. A. Rudick D. Woo 1999 Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins J. Neurochem. 72 741 750
37. C. Hesse L. Rosengren E. Vanmechelen 2000 Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke J. Alzheimer Dis. 2 199 206
38. K. Blennow A. Wallin H. Agren C. Spenger J. Siegfried E. Vanmechelen 1995 Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26 231 245
39. H. Hampel A. Goernitz K. Buerger 2003 Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Aβ1-42 proteins to phosphorylated tau proteins Brain Res. Bull. 61 243 253
40. P. J. Kahle M. Jakowec S. J. Teipel H. Hampel G. M. Petzinger D. A. Di Monte G. D. Silverberg H. J. Moller J. A. Yesavage J. R. Tinklenberg E. M. Shooter G. M. Murphy Jr. 2000 Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF Neurology 54 1498 1504
41. H. Hampel S. J. Teipel F. Padberg A. Haslinger M. Riemenschneider M. J. Schwarz H. U. Kotter M. Scheloske K. Buch S. Stubner R. Dukoff R. Lasser N. Muller T. Sunderland S. I. Rapoport H. J. Moller 1999 Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease Brain Res. 823 104 112
42. D. Scheuner C. Eckman M. Jensen X. Song M. Citron N. Suzuki T. D. Bird J. Hardy M. Hutton W. Kukull E. Larson E. Levy-Lahad M. Viitanen E. Peskind P. Poorkaj G. Schellenberg R. Tanzi W. Wasco L. Lannfelt D. Selkoe S. Younkin 1996 Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease Nat. Med. 2 864 870
43. R. Mayeux M. X. Tang D. M. Jacobs J. Manly K. Bell C. Merchant S. A. Small Y. Stern H. M. Wisniewski P. D. Mehta 1999 Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease Ann. Neurol. 46 412 416
44. A. Tamaoka T. Fukushima N. Sawamura K. Ishikawa E. Oguni Y. Komatsuzaki S. Shoji 1996 Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease J. Neurol. Sci. 141 65 68
45. K. E. Wisniewski H. M. Wisniewski G. Y. Wen 1985 Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome Ann. Neurol. 17 278 282
46. T. Tokuda T. Fukushima S. Ikeda Y. Sekijima S. Shoji N. Yanagisawa A. Tamaoka 1997 Plasma levels of amyloid beta proteins Abeta 1-40 and Abeta 1-42(43) are elevated in Down's syndrome Ann. Neurol. 41 271 273
47. P. D. Mehta A. J. Dalton S. P. Mehta K. S. Kim E. A. Sersen H. M. Wisniewski 1998 Increased plasma amyloid beta protein 1-42 levels in Down syndrome Neurosci. Lett. 241 13 16
48. M. R. Wilkins J. C. Sanchez A. A. Gooley R. D. Appel I. Humphery-Smith D. F. Hochstrasser K. L. Williams 1996 Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it Biotechnol. Genet. Eng. Rev. 13 19 50
49. J. Klose 1975 Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals Humangenetik 26 231 243
50. P. H. O'Farrell 1975 High resolution two-dimensional electrophoresis of proteins J. Biol. Chem. 250 4007 4021
51. B. Bjellqvist K. Ek P. G. Righetti E. Gianazza A. Görg R. Westermeier W. Postel 1982 Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications J. Biochem. Biophys. Methods 6 317 339
52. M. Fountoulakis 2004 Application of proteomics technologies in the investigation of the brain Mass. Spectrom. Rev. 23 231 258
53. C. Schöneich 2003 Proteomics in gerontological research Exp. Gerontol. 38 473 481
54. S. Aldred M. M. Grant H. R. Griffiths 2004 The use of proteomics for the assessment of clinical samples in research Clin. Biochem. 37 943 952
55. D. E. Comings 1982 Two-dimensional gel electrophoresis of human brain proteins. I. Technique and nomenclature of proteins Clin. Chem. 28 782 789
56. K. M. Mattila H. Frey 1994 Alzheimer brain proteins investigated by two-dimensional gel electrophoresis with immobilized pH gradients in the first dimension Electrophoresis 15 721 725
57. A. V. Smirnov P. N. Shevtsov G. S. Burbaeva 1991 Two-dimensional electrophoretic analysis of the protein spectrum of human brain structures in scizophrenia and senile dementia of the Alzheimer type Zh. Nevropatol. Psikhiatr. 91 34 36
58. M. G. Harrington C. R. Merril E. F. Torrey 1985 Differences in cerebrospinal fluid proteins between patients with schizophrenia and normal persons Clin. Chem. 31 722 726
59. I. Alafuzoff R. Adolfsson G. Bucht E. Jellum P. D. Mehta B. Winblad 1986 Isoelectric focusing and two-dimensional gel electrophoresis in plasma and cerebrospinal fluid from patients with dementia Eur. Neurol. 25 285 289
60. M. G. Harrington C. R. Merril D. M. Asher D. C. Gajdusek 1986 Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease N. Engl. J. Med. 315 279 283
61. L. E. Townsend J. Gilroy P. LeWitt D. E. Wolfe N. Pomara J. Weintraub D. Reitz 1987 Comparison of methods for analysis of CSF proteins in patients with Alzheimer's disease Neurochem. Pathol. 6 213 229
62. K. M. Mattila T. Pirttilä K. Blennow A. Wallin M. Viitanen H. Frey 1994 Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol. Scand. 89 192 198
63. C. Hesse C. L. Nilsson K. Blennow P. Davidsson 2001 Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization- time of flight-mass spectrometry Electrophoresis 22 1834 1837
64. L. H. Choe M. J. Dutt N. Relkin K. H. Lee 2002 Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease Electrophoresis 23 2247 2251
65. J. P. Blass A. Zemcov 1984 Alzheimer's disease. A metabolic systems degeneration? Neurochem. Pathol. 2 103 114
66. R. B. Scott 1993 Extraneuronal manifestations of Alzheimer's disease J. Am. Geriatr. Soc. 41 268 276
67. W. Jabbour A. Pouplard-Barthelaix R. Houlgatte J. Emile 1992 Abnormal expression of actin in lymphocytes of Alzheimer's disease and Down's syndrome patients J. Neuroimmunol. 38 199 208
68. K. M. Mattila H. Frey 1995 Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers Appl. Theor. Electrophor. 4 189 196
69. S. M. Cardoso M. T. Proenca S. Santos I. Santana C. R. Oliveira 2004 Cytochrome c oxidase is decreased in Alzheimer's disease platelets Neurobiol. Aging 25 105 110
70. D. Pratico 2005 Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead Neurobiol. Aging 26 581 583 discussion 587-595
71. D. Pratico C. M. Clark F. Liun J. Rokach V. Y. Lee J. Q. Trojanowski 2002 Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease Arch. Neurol. 59 972 976
72. J. N. Keller F. A. Schmitt S. W. Scheff Q. Ding Q. Chen D. A. Butterfield W. R. Markesbery 2005 Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology 64 1152 1156
73. I. Dalle-Donne R. Rossi D. Giustarini A. Milzani R. Colombo 2003 Protein carbonyl groups as biomarkers of oxidative stress Clin. Chim. Acta 329 23 38
74. M. A. Korolainen G. Goldsteins I. Alafuzoff J. Koistinaho T. Pirttilä 2002 Proteomic analysis of protein oxidation in Alzheimer's disease brain Electrophoresis 23 3428 3433
75. Korolainen, M. A., Goldsteins, G., Nyman, T. A., Alafuzoff, I., Koistinaho J., and Pirttilä, T. 2005. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol. Aging (in press)
76. D. A. Butterfield 2004 Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain Brain Res. 1000 1 7
77. J. Choi C. A. Malakowsky J. M. Talent C. C. Conrad R. W. Gracy 2002 Identification of oxidized plasma proteins in Alzheimer's disease Biochem. Biophys. Res. Commun. 293 1566 1570
78. H. L. Yu H. M. Chertkow H. Bergman H. M. Schipper 2003 Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma Proteomics 3 2240 2248
79. A. Goate M. C. Chartier-Harlin M. Mullan J. Brown F. Crawford L. Fidani L. Giuffra A. Haynes N. Irving L. James 1991 Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Nature 349 704 706
80. R. Sherrington E. I. Rogaev Y. Liang E. A. Rogaeve G. Levesque M. Ikeda H. Chi C. Lin G. Li K. Holman T. Tsuda L. Mar J. F. Foncin A. C. Bruni M. P. Montesi S. Sorbi I. Rainero L. Pinessi L. Nee I. Chumakov D. Pollen A. Brookes P. Sanseau R. J. Polinsky W. Wasco H. A. R. Da Silva J. L. Haines M. A. Pericak-Vance R. E. Tanzi A. S. Roses J. M. Fraser J. M. Rommens P. H. St. George-Hyslop 1995 Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease Nature 375 754 760
81. E. Levy-Lahad W. Wasco P. Poorkaj D. M. Romano J. Oshima W. H. Pettingell C. E. Yu P. D. Jondro S. D. Schmidt K. Wang A. C. Crowley Y. H. Fu S. Y. Guenette D. Galas E. Nemens E. M. Wijsman T. D. Bird G.D. Schellenberg R. E. Tanzi 1995 Candidate gene for the chromosome 1 familial Alzheimer's disease locus Science 269 973 977
82. E. I. Rogaev R. Sherrington E. A. Rogaeva G. Levesque M. Ikeda Y. Liang H. Chi C. Lin K. Holman T. Tsuda L. Mar S. Sorbi B. Nacmias S. Placentini L. Amaducci I. Chumakov D. Cohen L. Lannfelt P. E. Fraser J. M. Rommens P. H. St. George-Hyslop 1995 Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene Nature 376 775 778
83. K. Mattila C. Forssell T. Pirttilä J. Rinne T. Lehtimäki M. Röyttä L. Lilius A. Eerola St P. George-Hyslop H. Frey 1998 The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease Ann. Neurol. 44 965 967
84. G. Verdile S. Fuller C. S. Atwood S. M. Laws S. E. Gandy R. N. Martins 2004 The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol. Res. 50 397 409
85. E. H. Gorder A. M. Saunders W. J. Strittmatter D. E. Schmechel P. C. Gaskell G. W. Small A. D. Roses J. L. Haines M. A. Pericak-Vance 1993 Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 828 829
86. K. R. Bales J. C. Dodart R. B. DeMattos D. M. Holtzman S. M. Paul 2002 Apolipoprotein E, amyloid, and Alzheimer disease Mol. Interv. 2 363 375
87. M. I. Kamboh 1995 Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease Hum. Biol. 67 195 215
88. D. S. Knopman S. T. DeKosky J. L. Cumings J. Corey-Bloom N. Relkin 2001 Practice parameters: diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 1143 1153
89. A. Convit M. J. De Leon C. Tarshish S. De Santi W. Tsui H. Rusinek 1997 Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease Neurobiol. Aging 18 131 138
90. M. P. Laakso H. Soininen K. Partanen E. Helkala P. Hartikainen P. Vainio M. Hallikainen T. Hänninen P. Riekkinen Sr. 1995 Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions J. Neural. Transmission 9 73 86
91. N. C. Fox P. A. Freeborough 1997 Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease J. Magn. Reson. Imaging 7 1069 1075
92. N. C. Fox R. I. Scahill W. R. Crum M. N. Rossor 1999 Correlation between rates of brain atrophy and cognitive decline in AD Neurology 52 1687 1689
93. N. C. Fox E. K. Warrington P. A. Freeborough P. Hartikainen A. M. Kennedy J. M. Stevens 1996 Presymptomatic hippocampal atrophy in Alzheimer's disease A longitudinal MRI study Brain 119 Pt 6 2001 2007
94. N. C. Fox E. K. Warrington J. M. Stevens M. N. Rossor 1996 Atrophy of the hippocampal formation in early familiar Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717 Val-Gly mutation Ann. NY Acad. Sci. 777 226 232
95. W. E. Klunk H. Engler A. Nordberg Y. Wang G. Blomqvist 2004 Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann. Neurol. 55 306 319
96. M. Bobinski M. J. de Leon M. Tarnawski J. Wegiel B. Reisberg D. C. Miller H. M. Wisniewski 1998 Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer's disease Brain Res. 805 267 269
97. T. Heinonen P. Dastidar H. Eskola H. Frey P. Ryymin E. Laasonen 1998 Applicability of semi-automatic segmentation for volumetric analysis of brain lesions J. Med. Eng. Technol. 22 173 178
98. M. Weiner 2004 The use of MRI and PET for clinical diagnosis of dementia & investigation of cognitive impairment. A consensus report Neurobiol. Ageing 25 239 270
99. K. M. Mattila H. Frey 1996 Biomarkers in Alzheimer's disease? Path. Biol. 44 685 688